Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world AZD9291 monotherapy in EGFR T790M-positive advanced NSCLC after prior EGFR-TKI
2015-001407-31Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: overall survival. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-001407-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001407-31.